Industry experts in the Life Sciences partner with Elsevier
Amsterdam, 5 July 2005 - Elsevier, a leading publisher of scientific, technical and medical information, announces today that it convened its first Life Sciences Corporate Advisory Board meeting on Friday, 24 June at the Elsevier Amsterdam headquarters. The Advisory Board is comprised of a group of international decision makers from across the Life Sciences industry who provide their expertise on customer needs and advise Elsevier senior management on strategic direction.
According to Martin Tanke, Managing Director, Life Sciences, Elsevier: "The key objective of forming such an Advisory Board is to enhance communication and partnerships with our corporate customers. We were able to have a very open dialogue with our Advisory Board members to discuss their needs and expectations, as well as having the wealth of experience and knowledge from these leading experts to discuss relevant industry trends."
Dr. Steve Swain, Director of Published Information at GlaxoSmithKline, attended the first meeting and commented, "Corporate customers have been asking for some time for a forum to enable their views to be represented directly to Elsevier's senior management. This first meeting of the new Corporate Advisory Board was a great step forward, with a genuine two-way dialogue between the corporate members and the Elsevier management on a variety of strategic issues which face us all."
The Advisory Board membership includes representation from the following companies: BASF, BMS, Boehringer Ingelheim, Eli Lilly, F. Hoffman-La Roche, GlaxoSmithKline, Merck, NovoNordisk, Pfizer, sanofi-aventis and sienabiotech.
# # #About Elsevier
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence, and ClinicalKey — and publishes nearly 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.
The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
Name: Kate Alzapiedi
Phone: + 3120 485 3836